Literature DB >> 34855249

Overview of guideline recommendations for the management of high-risk and advanced cutaneous squamous cell carcinoma.

C Dessinioti1, A J Stratigos1.   

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer. National and international associations have issued evidence- and consensus-based guidelines to offer clinicians a framework to optimally manage patients with invasive cSCC. Current updated guidelines regarding the recommendations on the management of patients with high-risk and advanced cSCC include EDF/EADO (European) Guidelines 2020, US National Comprehensive Cancer Network guidelines 2021, American Academy of Dermatology guidelines 2018, British Association of Dermatology guidelines 2020 and German guidelines 2020. This review presents the guideline recommendations on the definition of high-risk and advanced cSCC, surgical treatment and safety margins, definitive and adjuvant radiotherapy and systemic treatments. The recommendations across guidelines may converge, diverge or in some cases not be able to provide a recommendation, highlighting open questions to be answered by future studies.
© 2021 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2022        PMID: 34855249     DOI: 10.1111/jdv.17531

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  2 in total

Review 1.  Recent Advances in the Diagnosis and Management of High-Risk Cutaneous Squamous Cell Carcinoma.

Authors:  Clio Dessinioti; Alexander J Stratigos
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

Review 2.  Clinical Characteristics of Actinic Keratosis Associated with the Risk of Progression to Invasive Squamous Cell Carcinoma: A Systematic Review.

Authors:  Alise Balcere; Laura Konrāde-Jilmaza; Laura Agnese Pauliņa; Ingrīda Čēma; Angelika Krūmiņa
Journal:  J Clin Med       Date:  2022-10-06       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.